Rethink of hepatectomy for hepatocellular carcinoma in the era of targeted immunotherapy

doi:10.3877/cma.j.issn.2095-3232.2024.01.003

Abstract

Abstract:

Surgery has been considered as the most effective treatment for hepatocellular carcinoma (HCC). In spite of almost 100-year development, the survival benefits brought by surgery for HCC patients have not been further improved. In recent years, widespread application of targeted drugs and immune checkpoint inhibitors have provided a novel development direction for comprehensive treatment and related research of HCC. With widespread clinical application, the advantages of targeted immune therapy in the treatment of HCC at all stages are constantly presented, which make surgeons rethink whether the original concept of surgery for HCC is still correct. In this article, the problems and potential solutions in hepatectomy for HCC in the era of targeted immunotherapy were in-depth discussed.

Key words: Carcinoma, hepatocellular, Target therapy, Immuno-therapy, Hepatectomy, Programmed death-1 (PD-1), Minimal residual disease (MRD)

Zhanguo Zhang. Rethink of hepatectomy for hepatocellular carcinoma in the era of targeted immunotherapy[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 11-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.01.003

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I01/11

References 24

[1]	Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma[J]. Ann Surg, 2023, 277(1):e103-111.
[2]	Goh EL, Chidambaram S, Ma S. Laparoscopic vs open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a meta-analysis of the long-term survival outcomes[J]. Int J Surg,2018(50):35-42.
[3]	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[4]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
[5]	Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970.
[6]	Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2021, 39(27):2991-3001.
[7]	Akce M, El-Rayes BF, Bekaii-Saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update[J]. Therap Adv Gastroenterol, 2022(15):17562848221086126.
[8]	Zhang B, Zhang B, Zhang Z, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation[J]. Sci China Life Sci, 2018, 61(6):660-670.
[9]	Zhang XP, Gao YZ, Chen ZH, et al. An Eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study[J]. Hepatology, 2019, 69(5):2076-2090.
[10]	Kamiyama T, Kakisaka T, Orimo T, et al. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus[J]. World J Hepatol, 2017, 9(36):1296-1304.
[11]	Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase Ⅲ RESORCE trial[J]. J Hepatol, 2018, 69(2):353-358.
[12]	中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6):618-632.
[13]	Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18):1906-1914.
[14]	Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3):490-505.
[15]	Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J].Ann Surg, 2020, 271(3):534-541.
[16]	Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg, 2021, 273(5):957-965.
[17]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022版)[J]. 中华消化外科杂志, 2022, 21(2):143-168.
[18]	Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment[J]. N Engl J Med, 2018, 379(18):1754-1765.
[19]	Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238.
[20]	Chin RI, Chen K, Usmani A, et al. Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)[J]. Mol Diagn Ther, 2019, 23(3):311-331.
[21]	Cucchetti A, Zhong J, Berhane S, et al. The chances of hepatic resection curing hepatocellular carcinoma[J]. J Hepatol, 2020, 72(4): 711-717.
[22]	Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J]. JAMA Surg, 2019, 154(3):209-217.
[23]	Colecchia A, Schiumerini R, Cucchetti A, et al. Prognostic factors for hepatocellular carcinoma recurrence[J]. World J Gastroenterol, 2014, 20(20):5935-5950.
[24]	Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005, 242(2):252-259.

Please choose a citation manager

Content to export